These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3047338)

  • 1. Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; Kochwa S; McIntyre OR; Glowienka LP; Brunner K; Rafla S; Coleman M; Cooper MR; Henderson E
    J Clin Oncol; 1988 Sep; 6(9):1481-90. PubMed ID: 3047338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
    J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
    Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
    J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
    Durie BG; Dixon DO; Carter S; Stephens R; Rivkin S; Bonnet J; Salmon SE; Dabich L; Files JC; Costanzi JJ
    J Clin Oncol; 1986 Aug; 4(8):1227-37. PubMed ID: 3525768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.
    Riccardi A; Merlini G; Montecucco C; Danova M; Ucci G; Cassano E; Ascari E
    Eur J Cancer Clin Oncol; 1986 Jul; 22(7):787-91. PubMed ID: 3770037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
    Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.
    Cohen HJ; Bartolucci AA; Forman WB; Silberman HR
    J Clin Oncol; 1986 Jun; 4(6):888-99. PubMed ID: 3519879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
    Boccadoro M; Marmont F; Tribalto M; Avvisati G; Andriani A; Barbui T; Cantonetti M; Carotenuto M; Comotti B; Dammacco F
    J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.
    Bladé J; San Miguel J; Alcalá A; Maldonado J; García-Conde J; Moro MJ; Sanz Sanz MA; Alonso C; Zubizarreta A; Besses C
    Blut; 1990 Jun; 60(6):319-22. PubMed ID: 2198075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
    Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Gyllenhammar H; Johansson B; Juliusson G; Järnmark M
    Eur J Haematol; 1989 Jul; 43(1):54-62. PubMed ID: 2670605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current results of a multicenter trial in multiple myeloma.
    Peest D; Schmoll HJ; Schedel I; Deicher H; Boll J; Essers U; Gamm H; Glück S; Görg K; Gramatzki M
    Onkologie; 1986 Jun; 9(3):168-9. PubMed ID: 3528964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
    Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
    Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
    [No Abstract]   [Full Text] [Related]  

  • 14. Response rate and survival in myeloma patients receiving prednisone alone.
    McIntyre OR; Pajak TF; Kyle RA; Cornwell GG; Leone L
    Med Pediatr Oncol; 1985; 13(5):239-43. PubMed ID: 4033539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.
    Hansen OP; Clausen NA; Drivsholm A; Laursen B
    Scand J Haematol; 1985 Nov; 35(5):518-24. PubMed ID: 3911373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study.
    Cooper MR; McIntyre OR; Propert KJ; Kochwa S; Anderson K; Coleman M; Kyle RA; Prager D; Rafla S; Zimmer B
    J Clin Oncol; 1986 Sep; 4(9):1331-9. PubMed ID: 3528403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group.
    Palva IP; Ahrenberg P; Ala-Harja K; Almqvist A; Apajalahti J; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Järvenpää E
    Eur J Haematol; 1987 Jan; 38(1):50-4. PubMed ID: 3582605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD).
    Bladé J; San Miguel J; Sanz-Sanz MA; Alcalá A; Hernández JM; Martínez M; García-Conde J; Moro J; Ortega F; Fontanillas M
    Eur J Cancer; 1992; 29A(1):57-60. PubMed ID: 1445746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy.
    Kildahl-Andersen O; Bjark P; Bondevik A; Bull O; Dehli O; Kvambe V; Nordahl E; Ytrehus K; Lamvik J
    Scand J Haematol; 1986 Sep; 37(3):243-8. PubMed ID: 3538367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; Leo R; Bartl R; Bartels H; Braun HJ; von Broen IM; Fischer JT; Gramatzki M
    Onkologie; 1990 Dec; 13(6):458-60. PubMed ID: 2092283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.